Dual RAS-blockade by ACE-inhibition and AT1 receptor blockade, role of the ACE I/D genotype and low sodium diet in non-diabetic proteinuric patients.

Recruiting

Conditions: non-diabetic proteinuria

Registration Number: NL-OMON23057

Brief Summary: Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial.<br> Slagman MC, Waanders F, Hemmelder MH, Woittiez AJ, Janssen WM, Lambers Heerspink HJ, Navis G, Laverman GD; HOlland NEphrology STudy Group. BMJ. 2011 Jul 26;343:d4366. doi: 10.1136/bmj.d4366. <br><br> PMID nummer van de plublicatie: 21791491

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 56

Inclusion Criteria

1. Age older than 18 year;
2. Chronic non-diabetic renal disease, as established by history, urine analysis, serum biochemistry tests and/or renal biopsy;
3. Creatinine clearance > 30 ml/min/1.73 m;
4. Residual proteinuria > 1 g/24h.

Exclusion Criteria

1. Failure to comply with the above inclusion criteria;
2. Diabetes mellitus;
3. Any contra-indication against the use of ACE inhibitors or AT1 receptor blockers;
4. A history of myocardial infarction, unstable angina, coronary by-pass or CVA during the past 6 months;
5. Heart failure NYHA class III-IV;
6. High rate of renal function loss (decline in creatinine clearance > 6 ml/min/1.73m2 during the previous year);
7. Need for treatment with corticosteroids, NSAID’s or immunosuppressive drugs;
8. Proteinuria > 10 g/24h and hypoalbuminaemia < 28 g/L;
9. Renovascular hypertension, malignant hypertension (diastolic blood pressure > 100 mmHg);
10. Serum potassium > 6 mmol/L.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary endpoint will be reduction of proteinuria and blood pressure expressed as percentage change from baseline and analysed with each patient as his or her own control.

Secondary Outcome Measures